Asset Details
Do you wish to reserve the book?
Raloxifene, a selective estrogen receptor modulator, is renoprotective: a post-hoc analysis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Raloxifene, a selective estrogen receptor modulator, is renoprotective: a post-hoc analysis
Do you wish to request the book?
Raloxifene, a selective estrogen receptor modulator, is renoprotective: a post-hoc analysis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Raloxifene, a selective estrogen receptor modulator, is renoprotective: a post-hoc analysis
2011
Overview
Estrogens have a protective effect on kidney fibrosis in several animal models. Here, we tested the effect of raloxifene, an estrogen receptor modulator, on the change in serum creatinine or estimated glomerular filtration rate (eGFR) and incident kidney-related adverse events. We performed a post-hoc analysis of the multiple outcomes of raloxifene evaluation trial, a double-masked, placebo-controlled randomized clinical trial encompassing 7705 post-menopausal women (aged 31–80 years) with osteoporosis. Participants were randomized to either of two doses of raloxifene, 60 or 120 mg/day, or placebo. Serum creatinine was measured at a central laboratory at baseline and annually. Adverse events were assessed every 6 months and uniformly categorized. Compared with those in the placebo group, participants on raloxifene had a slower yearly rate of increase in creatinine (significant at the low dose) and a significantly slower yearly rate of decrease in eGFR for both doses over 3 years of follow-up. Raloxifene was associated with significantly fewer kidney-related adverse events compared with placebo. Thus, treatment with raloxifene was safe and renoprotective. Clinical trials of raloxifene in post-menopausal women with kidney disease designed to look at kidney outcomes are needed to confirm these findings.
Publisher
Elsevier Inc,Nature Publishing Group,Elsevier Limited
Subject
/ Biological and medical sciences
/ Female
/ Fractures, Bone - prevention & control
/ Glomerular Filtration Rate - drug effects
/ Humans
/ Nephrology. Urinary tract diseases
/ Osteoporosis, Postmenopausal - drug therapy
/ Raloxifene Hydrochloride - administration & dosage
/ Raloxifene Hydrochloride - therapeutic use
/ randomized controlled trials
/ Renal Insufficiency, Chronic - physiopathology
/ Renal Insufficiency, Chronic - prevention & control
/ Selective Estrogen Receptor Modulators - administration & dosage
